Abstracts tagged "Antibodies"

Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…
Abstract Number: 2136 • 2017 ACR/ARHP Annual Meeting
Association of HLA-DQA1*05 with the Presence of Interstitial Lung Disease Independent of Autoantibody Status in Caucasian Patients with Polymyositis and Dermatomyositis
Adam Schiffenbauer¹, Sara Faghihi-Kashani², Terrance P. O'Hanlon¹, Willy Flegel³, Sharon Adams³, Ira N. Targoff⁴, Chester V. Oddis^5,6, Rohit Aggarwal^7,8, Lisa G Rider¹, Steven R. Ytterberg⁹, Lisa Christopher-Stine¹⁰, Sonye K. Danoff¹¹, Paul F. Dellaripa^12,13, Ejaz Shamim¹⁴, Andrew Mammen¹⁵ and Frederick W Miller¹⁶, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ³Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, ⁴VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Rheumatology/Clinical Immunology, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁸Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁹Rheumatology, Mayo Clinic, Rochester, MN, ¹⁰Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁴9. Department of Neurology, Mid-Atlantic Permanente Research Institute, Kaiser Permanente, Rockville, MD, ¹⁵Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD, ¹⁶Clinical Research Branch / Environmental Autoimmunity Group, NIH, Bethesda, MD
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication and a major contributor to mortality and morbidity in polymyositis and dermatomyositis (PM/DM). Prior studies have…
Abstract Number: 2139 • 2017 ACR/ARHP Annual Meeting
Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: PM and DM are inflammatory myopathies, sometimes complicated by interstitial lung disease (ILD), myocarditis, arthritis, and malignancies. The intensity of immunosuppressive therapies depends on…
Abstract Number: 2318 • 2017 ACR/ARHP Annual Meeting
Measurement of Serum Infliximab and Antibody Levels As an Adjunct to Clinical Decision Making Regarding Infliximab Therapy
Eileen Pagano¹, Myriam Kline² and B. Anne Eberhard³, ¹Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ²Biostatistics Unit, Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ³Pediatric Rheumatology, Cohen Children's Medical Center of New York, Lake Success, NY
Background/Purpose: Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-a). It is known to be effective and often used in the…
Abstract Number: 2876 • 2017 ACR/ARHP Annual Meeting
Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome
Tiezheng Yuan¹, Michelle Petri², Alan N. Baer³ and H. Benjamin Larman¹, ¹Pathology (Immunology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: An unbiased and comprehensive approach to the analysis of Sjögren’s syndrome (SS) antibody repertoires would provide important data on its pathogenesis. Phage ImmunoPrecipitation sequencing…
Abstract Number: 1011 • 2016 ACR/ARHP Annual Meeting
Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome
Joseph LaConti¹, Fanny Kippelen², Rohit Aggarwal³ and Dana P. Ascherman⁴, ¹Division of Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ²Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL
Correlations Between B Cell Epitope Specificity and Clinical Features in Patients with Jo-1 Antibodies and the Anti-Synthetase Syndrome Background/Purpose: Idiopathic inflammatory myopathy (IIM) is an…
Abstract Number: 3243 • 2016 ACR/ARHP Annual Meeting
Intestinal Microbial Dysbiosis in SLE Is Linked to Elevated IgA and Induction of Autoimmunity
Doua F. Azzouz¹, Lelise Getu², Celine Anquetil¹, Jill P. Buyon³ and Gregg J. Silverman³, ¹Medicine, NYU School of Medicine, New York, NY, ²Department of Medicine, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY
Background/Purpose: SLE is a complex multifactorial systemic autoimmune disease, which has been attributed to poorly understood interactions between genetic and environmental factors. Recent reports have…
Abstract Number: 1347 • 2016 ACR/ARHP Annual Meeting
Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis: Characteristics, Treatment and Outcome in 251 Cases from the Literature
Charlotte Laurent¹, Jean Capron², Sonia Alamowitch³, Bluenn Quillerou⁴, Guy Thomas⁴, Olivier Fain⁵ and Arsène Mékinian⁵, ¹Internal Medicine, Internal Medicine, Hôpital Saint-Antoine, Paris, paris, France, ²Neurology, Neurology, Hôpital Saint-Antoine, paris, France, ³Neurology, Neurology - Hopital St Antoine, paris, France, ⁴Psychiatry, Psychiatry Hopital St Antoine, paris, France, ⁵Service de médecine interne. Hôpital Saint-Antoine., Paris, France
Background/Purpose: Steroid-responsive encephalopathy and associated autoimmune thyroiditis (SREAT) is characterized by encephalopathy and the presence of antithyroid antibodies. We describe the clinical presentation, outcome and…
Abstract Number: 1353 • 2016 ACR/ARHP Annual Meeting
Risk Factors of Pulmonary Mycobacterium Avium-Comlex (MAC) Disease and the Significance of Anti-MAC Antibody in Patients with Rheumatic Diseases
Tamao Nakashita¹, Shinji Motojima², Akira Jibatake², Akira Yoshida² and Yoshiki Yamamoto², ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa-city, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: Pulmonary MAC disease is caused by MAC and the incidence is increasing in Japan. It is also becoming a great concern in the field…
Abstract Number: 1369 • 2016 ACR/ARHP Annual Meeting
Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Takayuki Kishi², Nastaran Bayat², Ira N. Targoff³, Lan Wu², Olcay Y. Jones^1,4, Rodolfo Curiel¹, Frederick W. Miller² and Lisa G. Rider^1,2, ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD, ³University of Oklahoma, Oklahoma City, OK, ⁴Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Clinically Amyopathic Juvenile Dermatomyositis (CAJDM) is a distinct clinical phenotype of JDM in which patients (pts) often have characteristic JDM rashes with little…
Abstract Number: 1437 • 2016 ACR/ARHP Annual Meeting
Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Aranzazu Mediero¹, Tuere Wilder², Bhama Ramkhelawon³, Kathryn Moore³ and Bruce Cronstein⁴, ¹Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, ²Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, ⁴Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of joints. Netrin-1, a laminin-like matrix protein that acts as a…
Abstract Number: 1667 • 2016 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Axial Spondyloarthritis: Results from a Population with Low HLA-B27 Prevalence Background
Nelly Ziade¹, Fouad Fayad¹, Iyad Mallak², Georges Merheb³, Torsten Witte⁴ and Xenofon Baraliakos⁵, ¹Rheumatology, Hotel Dieu de France Hospital and Saint Joseph University, Beirut, Lebanon, ²Radiology, Hotel-Dieu de France and Saint-Joseph University, Beirut, Lebanon, ³Internal Medicine, Notre Dame des Secours University Hospital, Jbeil, Lebanon, ⁴Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ⁵Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is still frequently diagnosed late and its pathogenesis is still unclear. Although a strong genetic association of axSpA with HLA-B27 is…
Abstract Number: 1876 • 2016 ACR/ARHP Annual Meeting
Prevalence of Anti-RNA Polymerase III IgG Antibody in a Cohort of Patients with Delayed Wound Healing
Christian Geier¹, Sean McNish² and Victoria K. Shanmugam², ¹Department of Medicine, The George Washington University, Washington, DC, ²Division of Rheumatology, The George Washington University, Washington, DC
Prevalence of Anti-RNA Polymerase III IgG Antibody in a Cohort of Patients with Delayed Wound Healing Background/Purpose: Anti-RNA polymerase III IgG antibody (Pol3) is associated…
Abstract Number: 2454 • 2016 ACR/ARHP Annual Meeting
Cohort of Pregnant Women with Ro/La Antibodies: Risk of Fetal Third Degree Atrioventricular Block and Use of Hydroxychloroquine
Florencia Beatriz Mollerach¹, Marina Scolnik², Luis J. Catoggio² and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina
Background/Purpose: Third degree atrioventricular block(AVB), a rare congenital complication, duplicate-triplicate frequency up to 2% when Ro/La maternal antibodies are present. Incidence rises to 17-20% in…
Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting
Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Chamaida Plasencia-Rodriguez¹, Ana Martínez², Alejandro Villalba³, Teresa Jurado⁴, Eva Olariaga-Merida⁵, Araceli Mezcua⁶, Diana Peiteado³, Gema Bonilla³, Laura Nuño³, Alejandro Balsa¹ and Dora Pascual-Salcedo², ¹Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁵Immunology, University Hospital La Paz, Madrid, Spain, ⁶Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].